Full-year revenue for 2025 was $1.7 million, representing a 40% growth over the previous year. Q4 revenue growth was 133% year-over-year. Operating expenses for the year were down $4.8 million, or 17%, compared to the previous year. Net loss was down 14% for the year versus 2024. Net cash used in operating activities was $19.7 million for the year, down 24%. Received the first order for Nu.Q Cancer assays for clinical certification ahead of routine clinical use in lung cancer. Nu.Q NETs assay was included in a real-world interventional evaluation of early detection of sepsis, in a government-backed program worth approximately $7.3 million in France. Engaged in discussions with around 10 of the world's leading diagnostic and liquid biopsy companies for human diagnostics licensing agreements. Subsequent to year-end, the company received $5.4 million in net proceeds from equity sales, $1.9 million in net proceeds from issuance of a convertible note and warrant, and $1.0 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected.